The Growing Case For AI To Support Pharmacovigilance: World Drug Safety Congress Americas Key Takeaways

By Stephen Sun, Lin Li, and Devendrakumar Patel, Cencora

Discussions at this past year's World Drug Safety Congress highlighted a pivotal shift in pharmacovigilance: the move from observing AI to actively piloting it within safety workflows. While extensive use remains limited, with only 7% of organizations currently employing AI to summarize safety cases, the focus has turned toward automating the transcription and validation of Individual Case Safety Reports. These advancements aim to manage rising case volumes without replacing critical human oversight. Success in this area relies on standardizing data before implementation and upskilling teams to work alongside automated systems.

Aligning these tools with regulatory expectations ensures that efficiency gains also support inspection readiness. Read the full insights from the conference to evaluate how these evolving strategies can refine your signal management and reporting processes.